Pharmacokinetic Effects of Coadministration of Lersivirine with Raltegravir or Maraviroc in Healthy Subjects
Manoli Vourvahis(Pfizer (United States)), John D. Davis(Providence College), Subhashis Banerjee(Bristol-Myers Squibb (United States)), Robert R. LaBadie(Pfizer (United States)), Grant Langdon, Marie-Noella Ndongo(Pfizer (United States)), Gary Layton(University of Geneva)
Cited by 7
Related Papers
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2014|488
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
|Journal of the American Academy of Dermatology|2020|396